Back
to home » Treatment News » Top Stories
 September 30, 2008
|
Once-Daily Prezista as Good as Twice-Daily Dose for Some
Once-daily Norvir (ritonavir)-boosted Prezista (darunavir) is as effective as standard twice-daily dosing for some treatment-experienced patients, according to a study published in the October issue of the Journal of Acquired Immune Deficiency Syndromes.
|
|
|
| September 29, 2008
|
September 26, 2008
|
Zetia Reduces LDL in People Living With HIV
Zetia (ezetimibe) may be an effective option for HIV-positive patients who had moderately elevated low-density lipoprotein (LDL) levels—the “bad” form of cholesterol—and were on antiretroviral therapy (ARV), based on a small clinical trial reported in the October 15 issue of Clinical Infectious Diseases.
|
|
|
September 25, 2008
|
Tropism Testing May Help Predict Disease Progression
Tropism testing, which detects the presence of HIV that uses the CXCR4 (X4) coreceptor, is currently used to determines whether a patient may be able to use Pfizer’s entry inhibitor Selzentry (maraviroc). Now, a new study indicates that the test may also pinpoint a greater risk of AIDS-related health problems, even in people with high CD4 cell counts who are not yet on treatment—and may even help guide when to start or switch antiretroviral (ARV) therapy.
|
|
|
September 24, 2008
|
HIV Treatment Diminishes Non-AIDS Illnesses
Antiretroviral (ARV) therapy significantly decreases the risk of non-AIDS-related illnesses in people with CD4 counts below 350, according to a study published in the October 15 issue of Clinical Infectious Diseases and reported by aidsmap.com.
|
|
|
September 23, 2008
|
Twice-Daily Retrovir Now OK for Kids
Retrovir (zidovudine) may now be used twice daily in HIV-positive children ages six weeks to 18 years and can be dosed by weight, according to an announcement by the United States Food and Drug Administration (FDA).
|
|
|
Nipple Shield Filters HIV From Breast Milk
A British chemical engineer has designed a thin nipple shield that he claims can filter HIV out of the breast milk of HIV-positive mothers, according to a report by the BBC News.
|
|
|
September 22, 2008
|
Relocation of Gut Bacteria Linked to Low CD4s
In some people living with HIV, bacteria normally contained within intestinal lymph nodes are relocated to the blood stream. This process is associated with a lack of increase in CD4 cells —even in people whose HIV viral load is undetectable—according to a study in the October 1 issue of AIDS.
|
|
|
September 19, 2008
|
Why Some Primates Aren’t Vulnerable to SIV
Scientists have discovered key biological differences that may explain why some primates don’t get sick despite being infected with simian immunodeficiency virus (SIV)—a virus almost identical to HIV—according to a Nature Medicine study reported by Science Daily.
|
|
|
September 18, 2008
|
New Maturation Inhibitor Enters Phase 2 Testing
Vivecon (MPC-9055), a new maturation inhibitor, is moving into early Phase 2 studies. The experimental antiretroviral will be studied in HIV-positive people to determine the proper dose of the drug, according to a press release from Myriad Genetics.
|
|
|
September 17, 2008
|
Chamomile May Help Prevent Diabetes and Its Complications
Properties in chamomile, including a tea made from the flower, have a number of anti-diabetes effects in rats, according to new findings published in the Journal of Agricultural and Food Chemistry by researchers in the United Kingdom and Japan.
|
|
|
| September 16, 2008
|
September 15, 2008
|
Acyclovir Also Fights HIV in People With Herpes
A team of researchers has identified how the anti-herpes drug acyclovir (Zovirax) limits HIV replication in people coinfected with herpes simplex virus (HSV), according to a report published in the September 11 issue of Cell Host & Microbe.
|
|
|
September 12, 2008
|
People Now Able to Stay on First Antiretroviral Regimens Longer
People living with HIV are now able to remain on a first antiretroviral (ARV) regimen—which now usually includes once daily dosing and fewer pills—for much longer than people taking older twice-daily, multiple pill regimens, according to the authors of a study published in the October 1 issue of AIDS.
|
|
|
HIV Stigma Hinders Access to Care and Prevention
The stigma surrounding HIV has kept people infected with the virus in the Arkansas delta region from coming forward for health services, including antiretroviral treatment, according to a panelist at a meeting earlier this month in Little Rock and was reported on by the Arkansas Democrat Gazette.
|
|
|
September 11, 2008
|
HIV Status Unknown for Most “Negative” Men Online
Seventeen percent of HIV-positive men who have sex with men (MSM) and nearly three quarters of MSM who’ve never been tested for HIV say they are HIV negative in their online profiles, according to a study published in the September issue of the Journal of Urban Health.
|
|
|
September 10, 2008
|
Further Possible Benefits of PrEP
Intermittent use of Truvada (tenofovir plus emtricitabine) by an HIV-negative gay man who had multiple instances of unprotected anal sex didn’t prevent him from becoming infected, but did appear to help preserve a strong immune response to the virus.
|
|
|
September 09, 2008
|
High Rate of Circumcision Side Effects in Kenyan Survey
Male circumcision may be associated with a lower risk of HIV infection in clinical trials, but the results of a survey involving 1,007 boys and young men in Kenya describe its high rates of side effects in a real-world setting as “shocking” and “unacceptable.”
|
|
|
September 08, 2008
|
Researchers Link Gene to Key Antibody Responses
A powerful gene controls the production of antibodies that effectively neutralize human retroviruses such as HIV, according to new laboratory research conducted by scientists at UCSF and NIAID. This may explain why most humans who are infected with HIV do not make neutralizing antibodies that successfully fight the virus.
|
|
|
September 05, 2008
|
PAD Common in HIV-Positive Patients Over 50
Peripheral arterial disease (PAD) was found in just over 10 percent of a group of HIV-positive patients older than 50, according to the authors of a study published in the September issue of AIDS Research and Human Retroviruses.
|
|
|
September 04, 2008
|
Genes, Not Race, Should Guide Antiretroviral Treatment
A person’s genetic sequence, and not his or her race, should guide scientists and health care providers in the design of clinical trials and treatment decisions with antiretroviral (ARV) drugs such as efavirenz (found in Sustiva and Atripla), according to a review article published in the September 1 issue of AIDS.
|
|
|
September 03, 2008
|
Vistide Not Effective in Treating PML
The addition of Vistide (cidofovir) to antiretroviral (ARV) therapy did not slow disease progression or prevent death in HIV-positive people with progressive multifocal leukoencephalopathy (PML), according to a study in the September 1 issue of AIDS.
|
|
|
September 02, 2008
|
Norvir and Heart Conduction Disturbances
People taking 400 mg or more of Norvir (ritonavir) twice-daily may have delayed conduction of electrical charges in their hearts, according to a notice from the U.S. Food and Drug Administration (FDA) detailing revisions to Norvir’s prescribing information.
|
|
|
Worsening Depression in Four Patients on Isentress
Four patients who switched to a regimen containing Isentress (raltegravir) had a temporary worsening of preexisting depression, according to a letter in the September 12 issue of AIDS that was reported by aidsmap.com.
|
|
|
|
|
|
 |
|
